Alkermes plc (ALKS)
NASDAQ: ALKS · IEX Real-Time Price · USD
24.68
+0.24 (0.98%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Alkermes Employees
Alkermes had 2,100 employees on February 9, 2024. The number of employees decreased by 180 or -7.89% compared to the previous year.
Employees
2,100
Change (1Y)
-180
Growth (1Y)
-7.89%
Revenue / Employee
$792,098
Profits / Employee
$169,408
Market Cap
4.12B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Feb 9, 2024 | 2,100 | -180 | -7.89% |
Feb 10, 2023 | 2,280 | 69 | 3.12% |
Feb 4, 2022 | 2,211 | -34 | -1.51% |
Feb 5, 2021 | 2,245 | 10 | 0.45% |
Feb 4, 2020 | 2,235 | -65 | -2.83% |
Feb 4, 2019 | 2,300 | 300 | 15.00% |
Feb 2, 2018 | 2,000 | 250 | 14.29% |
Feb 3, 2017 | 1,750 | 250 | 16.67% |
Feb 12, 2016 | 1,500 | 200 | 15.38% |
Feb 12, 2015 | 1,300 | 50 | 4.00% |
Feb 13, 2014 | 1,250 | 20 | 1.63% |
May 8, 2013 | 1,230 | 30 | 2.50% |
May 10, 2012 | 1,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Integer Holdings | 10,500 |
Perrigo Company | 9,140 |
Merit Medical Systems | 6,950 |
iRhythm Technologies | 2,000 |
Ultragenyx Pharmaceutical | 1,276 |
Alvotech | 1,026 |
Insmed | 912 |
Immunovant | 164 |
ALKS News
- 3 days ago - Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 - PRNewsWire
- 10 days ago - Alkermes to Report First Quarter Financial Results on May 1, 2024 - PRNewsWire
- 18 days ago - Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia - PRNewsWire
- 19 days ago - Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society - PRNewsWire
- 7 weeks ago - Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors - PRNewsWire
- 2 months ago - Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 - PRNewsWire
- 2 months ago - Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 - PRNewsWire
- 4 months ago - Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference - PRNewsWire